BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Campbell C, Andersson MI, Ansari MA, Moswela O, Misbah SA, Klenerman P, Matthews PC. Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era. Front Med (Lausanne) 2021;8:706482. [PMID: 34490299 DOI: 10.3389/fmed.2021.706482] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Li A, He Y, Yang C, Lu N, Bao J, Gao S, Hosyanto FF, He X, Fu H, Yan H, Ding N, Xu L. Methylprednisolone Promotes Mycobacterium smegmatis Survival in Macrophages through NF-κB/DUSP1 Pathway. Microorganisms 2023;11:768. [DOI: 10.3390/microorganisms11030768] [Reference Citation Analysis]
2 Leke Wiering, Frank Tacke. Versorgung von Lebertransplantierten während der COVID-19-Pandemie. Gastroenterologie 2023. [ DOI: 10.1007/s11377-023-00675-6] [Reference Citation Analysis]
3 Cornberg M, Dietz-fricke C. Therapie von COVID-19 unter Berücksichtigung von Lebererkrankungen. Gastroenterologie 2023. [DOI: 10.1007/s11377-023-00681-8] [Reference Citation Analysis]
4 Walia D, Saraya A, Gunjan D. COVID-19 in patients with pre-existing chronic liver disease – predictors of outcomes. World J Virol 2023; 12(1): 30-43 [DOI: 10.5501/wjv.v12.i1.30] [Reference Citation Analysis]
5 Khazaaleh S, Alomari M, Sharma S, Kapila N, Zervos XB, Gonzalez AJ. COVID-19 in liver transplant patients: Impact and considerations. World J Transplant 2023; 13(1): 1-9 [PMID: 36687560 DOI: 10.5500/wjt.v13.i1.1] [Reference Citation Analysis]
6 Brandi N, Spinelli D, Granito A, Tovoli F, Piscaglia F, Golfieri R, Renzulli M. COVID-19: Has the Liver Been Spared? Int J Mol Sci 2023;24. [PMID: 36674607 DOI: 10.3390/ijms24021091] [Reference Citation Analysis]
7 Mathilde Garé, Michael Thy, Laurène Deconinck, Nathalie Grall, Yazdan Yazdanpanah, Véronique Joly. Réactivation de tuberculose après traitement immunomodulateur pour une infection sévère à SARS-CoV-2. Médecine et Maladies Infectieuses Formation 2022. [ DOI: 10.1016/j.mmifmc.2022.12.003] [Reference Citation Analysis]
8 Tacke F, Cornberg M, Sterneck M, Trebicka J, Settmacher U, Bechstein WO, Berg T; Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), vertreten durch Frank Tacke, Markus Cornberg, Martina Sterneck, Jonel Trebicka, Thomas Berg, Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV), vertreten durch Wolf Bechstein. S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie – AWMF-Registernummer: 021-031 – Stand 15. Juni 2022. Z Gastroenterol 2022;60:1678-98. [PMID: 36368659 DOI: 10.1055/a-1934-1989] [Reference Citation Analysis]
9 Rezaei Tolzali MM, Noori M, Shokri P, Rahmani S, Khanzadeh S, Nejadghaderi SA, Fazlollahi A, Sullman MJM, Singh K, Kolahi AA, Arshi S, Safiri S. Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review. Rev Med Virol 2022;:e2388. [PMID: 36029180 DOI: 10.1002/rmv.2388] [Reference Citation Analysis]
10 Ramón A, Zaragozá M, Torres AM, Cascón J, Blasco P, Milara J, Mateo J. Application of Machine Learning in Hospitalized Patients with Severe COVID-19 Treated with Tocilizumab. J Clin Med 2022;11:4729. [PMID: 36012968 DOI: 10.3390/jcm11164729] [Reference Citation Analysis]
11 Sagnelli C, Montella L, Grimaldi P, Pisaturo M, Alessio L, De Pascalis S, Sagnelli E, Coppola N. COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature. Pathogens 2022;11:816. [DOI: 10.3390/pathogens11070816] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
12 Mohseni Afshar Z, Barary M, Babazadeh A, Tavakoli Pirzaman A, Hosseinzadeh R, Alijanpour A, Allahgholipour A, Miri SR, Sio TT, Sullman MJM, Carson-Chahhoud K, Ebrahimpour S. The role of cytokines and their antagonists in the treatment of COVID-19 patients. Rev Med Virol 2023;33:e2372. [PMID: 35621229 DOI: 10.1002/rmv.2372] [Reference Citation Analysis]
13 Sagnelli C, Sica A, Creta M, Borsetti A, Ciccozzi M, Sagnelli E. Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19. Pathogens 2022;11:567. [DOI: 10.3390/pathogens11050567] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Yuan WZ, Fu T. Liver Dysfunction in COVID-19: From Onset to Recovery. Semin Liver Dis 2022;42:151-8. [PMID: 35738256 DOI: 10.1055/s-0042-1745871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Noori MAM, Younes I, Latif A, Fichadiya H, Elkattawy S, Khandait H, Nawachukwu O, Garg V. Reactivation of Tuberculosis in the Setting of COVID-19 Infection. Cureus 2022. [DOI: 10.7759/cureus.23417] [Reference Citation Analysis]
16 Yip TC, Gill M, Wong GL, Liu K. Management of hepatitis B virus reactivation due to treatment of COVID-19. Hepatol Int 2022. [PMID: 35235148 DOI: 10.1007/s12072-022-10306-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Johnston P, Linton E, Ankcorn M, Mitchell C, Stone B. Navigating past and current hepatitis B infection in primary care. Br J Gen Pract 2021;71:474-6. [PMID: 34593404 DOI: 10.3399/bjgp21X717341] [Reference Citation Analysis]